explore -WSS

explore

author：comprehensive 2025-09-01 15:21:07 - browse：77

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： California store owner shot dead in dispute over displaying Pride flag: Police

WSS

FDA advisory panel to debate high blood pressure devices

Vivek Ramaswamy made waves in the debate, much as in biotech

California store owner shot dead in dispute over displaying Pride flag: Police

How the drug

FDA greenlights medical device to combat bladder issues

Illinois Supreme Court finds assault weapons ban constitutional

knowledge

explore

explore

Drug repurposing or repositioning? The language matters

People can get long Covid without testing positive for virus: Study

Walensky prepares to leave CDC — and Congress — behind

How the first Native Hawaiian psychiatrist helped diversify medicine

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Can U.S. cancer drug shortages be fixed?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Health AI: on the border between health care and tech

The cancer drug shortage isn’t new — and neither are the solutions

After Optum profits sink, UnitedHealth makes changes

hotspot

Indictment alleges Trump's ex

How the drug

FDA greenlights medical device to combat bladder issues

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Biden administration begins canceling student loan debt for 804,000 borrowers

FDA advisory panel to debate high blood pressure devices

focus

leisure time

Wikipedia

hotspot